| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 4,860 | 0 | 0 | 1,450 | 660 |
| Sales Growth | unch | unch | -100.00% | +119.70% | -26.67% |
| Net Income | -23,360 | 98,090 | -112,660 | -56,520 | -59,880 |
| Net Income Growth | -123.81% | +187.07% | -99.33% | +5.61% | +9.25% |
Aceragen Inc (ACGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aceragen Inc. is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. Its portfolio includes late-stage programs based on well-established biological principles. Aceragen Inc., formerly known as Idera Pharmaceuticals Inc., is based in DURHAM, N.C.
Fiscal Year End Date: 12/31